β-blockers: A new role in cancer chemotherapy?

Expert Opinion on Investigational Drugs

Volumn 22, Issue 11, 2013, Pages 1359-1363

  Nagaraja, Archana S ^a   Sadaoui, Nouara C ^a   Lutgendorf, Susan K ^b   Ramondetta, Lois M ^a   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

adrenergic receptor; blockers; Catecholamines

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NADOLOL; NORADRENALIN; PROPRANOLOL; TIMOLOL;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CAPILLARY HEMANGIOMA; DISEASE FREE INTERVAL; DISTANT METASTASIS FREE SURVIVAL; DRUG TUMOR LEVEL; HEMANGIOMA; HUMAN; HYPERTENSION; LUNG NON SMALL CELL CANCER; MELANOMA; OVARY CARCINOMA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RECURRENCE FREE SURVIVAL; REVIEW; TRIPLE NEGATIVE BREAST CANCER; TUMOR RECURRENCE;

ADJUVANTS, PHARMACEUTIC; ADRENERGIC BETA-ANTAGONISTS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; NEOPLASMS;

EID: 84885780718     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.825250     Document Type: Review

References (15)

1. Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr 2004(32):57-71
2. Lutgendorf SK, DeGeest K, Dahmoush L, et al. Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients. Brain Behav Immun 2011;25(2):250-5
3. Costanzo ES, Lutgendorf SK, Sood AK, et al. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer 2005;104(2):305-13
4. Soygur H, Palaoglu O, Akarsu ES, et al. Interleukin-6 levels and HPA axis activation in breast cancer patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(6):1242-7
5. Grytli HH, Fagerland MW, Fossa SD, et al. Association between use of beta-blockers and prostate cancer-specific survival: A cohort study of 3561 prostate cancer patients with high-risk or metastatic disease. Eur Urol 2013;64(1):e11-12
6. Shang ZJ, Liu K, Liang de F. Expression of beta2-adrenergic receptor in oral squamous cell carcinoma. J Oral Pathol Med 2009;38(4):371-6
7. Diaz ES, Karlan BY, Li AJ. Impact of beta blockers on epithelial ovarian cancer survival. Gynecol Oncol 2012;127(2):375-8
8. Powe DG, Voss MJ, Zanker KS, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010;1(7):628-38
9. Barron TI, Connolly RM, Sharp L, et al. Beta blockers and breast cancer mortality: A population-based study. J Clin Oncol 2011;29(19):2635-44
10. Lemeshow S, Sørensen HT, Phillips G, et al. Beta-blockers and survival among danish patients with malignant melanoma: A population-based cohort study. Cancer Epidemiol Biomarkers Prev 2011;20(10):2273-9
11. Wang HM, Liao ZX, Komaki R, et al. Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy. Ann Oncol 2013;24(5):1312-19
12. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008;358(24):2649-51
13. Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 2011;29(19):2645-52
14. Heitz F, du Bois A, Harter P, et al. Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer- A combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG. Gynecol Oncol 2013
15. Armaiz-Pena GN, Allen JK, Cruz A, et al. Src activation by beta-drenoreceptors is a key switch for tumour metastasis. Nat Commun 2013;4:1403